Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes

Leukemia Research

Volumn 30, Issue 4, 2006, Pages 385-388

  Musto, Pellegrino ^a   Falcone, Antonietta ^a   Sanpaolo, Grazia ^a   Bodenizza, Carlo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Anemia; Erythropoietin; Myelodysplastic syndromes; Thalidomide; Thrombosis; Transfusions

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; ERYTHROCYTE TRANSFUSION; ERYTHROID CELL; FEMALE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 32844465496     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.08.020     Document Type: Article

References (24)

1. E. Hellstrom-Lindberg Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients fron 17 studies Br J Haematol 89 1995 67 71
2. Italian Cooperative Study Group for r-Hu-Epo in Myelodysplastic Syndromes. A randomized, double-blind, placebo-controlled study with subcutaneous human erythropoietin in patients with low risk myelodysplastic syndromes Br J Haematol 103 1998 1070 1074
3. P. Musto, A. Falcone, G. Sanpaolo, C. Bodenizza, A. La Sala, and G. Perla Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes Br J Haematol 122 2003 269 271
4. M.A. Aloe-Spiriti, R. Latagliata, P. Niscola, A. Cortelezzi, M. Francescani, and D. Ferrari Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome Ann Hematol 84 2005 167 176
5. A. Raza, P. Mayer, D. Dutt, F. Zorat, L. Lisak, and F. Nascimben Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 98 2001 958 965
6. C. Strupp, U. Germing, M. Aivado, E. Misgeld, R. Haas, and N. Gattermann Thalidomide in the treatment of patients with myelodysplastic syndromes Leukemia 16 2002 1 6
7. P. Musto, A. Falcone, G. Sanpaolo, M. Bisceglia, R. Matera, and A.M. Carella Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes Haematologica 87 2002 884 886
8. D. Bowen, L. Mac Ilwaine, J. Cavanagh, S. Killick, D. Culligan, and E. Thomson Thalidomide therapy for low-risk myelodysplasia Leuk Res 29 2005 235 236
9. E. Hellstrom-Lindberg Approach to anemia of myelodysplastic syndromes Curr Hematol Rep 2 2003 122 129
10. P. Musto Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes Clin Lymphoma 6 2005 2 5
11. P. Musto Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives Leuk Res 28 2004 325 332
12. P.L. Greenberg, C. Cox, M.M. LeBeau, P. Fenaux, P. Morel, and G. Sanz International scoring system for evaluating prognosis of myelodysplastic syndromes Blood 89 1997 2079 2088
13. N.L. Harris, E.S. Jaffe, J. Diebold, G. Flandrin, H.K. Muller-Hermelink, and J. Vardiman World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol 17 1999 3835 3849
14. B.D. Cheson, J.M. Bennett, H. Kantarjian, A. Pinto, C.A. Schiffer, S.D. Nimer World Health Organization (WHO) International Working Group. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674
15. R. Stasi, M. Brunetti, E. Terzoli, and S. Amadori Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes Blood 99 2002 578 584
16. E. Hellstrom-Lindberg, N. Gulbrandsen, G. Lindberg, T. Ahlgren, I.M. Dahl, and I. Dybedal A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 2003 1037 1046
17. R.S. Negrin, R. Stein, K. Doherty, J. Cornwell, J. Vardiman, and S. Krantz Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy Blood 87 1996 4076 4081
18. N. Casadevall, P. Durieux, S. Dubois, F. Hemery, E. Lepage, and M.C. Quarre Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 104 2004 321 327
19. P. Musto, G. Sanpaolo, G. D'Arena, P. Scalzulli, R. Matera, and A. Falcone Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone Haematologica 86 2001 44 51
20. A. Grossi, P. Musto, V. Santini, F. Balestri, A. Fabbri, and A. Falcone Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes Haematologica 87 2002 322 323
21. A. Tefferi, M.A. Elliot, D.P. Steensma, C.C. Hook, A. Dispenzieri, and C.A. Hanson Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndromes Leuk Res 25 2001 1853 1855
22. A. Candoni, A. Raza, F. Silvestri, L. Lisak, N. Galili, and M. Mumtaz Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes Ann Hematol 84 2005 479 481
23. A. Raza, S. Buonamici, L. Lisak, S. Tahir, D. Li, and M. Imran Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression Leuk Res 28 2004 791 803
24. M. Steurer, I. Sudmeier, R. Stauder, and G. Gastl Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha Br J Haematol 121 2003 101 103